地中海贫血临床试验招募信息（全球在招）

这里汇总了全球正在招募患者的 地中海贫血（国际通用名 thalassemia）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖地贫等说法。

正在招募的地中海贫血新药试验

• T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

  I 期 / II 期招募中美国NCT03653338

• Long-term Follow-up Study of BRL-101 for TDT

  不适用招募中中国NCT06298630

• A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

  不适用招募中South KoreaNCT06073860

• International Registry of Patients With Alpha Thalassemia

  不适用招募中美国NCT04872179

• A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

  不适用招募中KuwaitOmanSaudi ArabiaUnited Arab EmiratesNCT07215975

• Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

  不适用招募中美国NCT03775954

• Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

  II 期招募中PakistanNCT06490627

• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

  II 期招募中美国NCT04099966

• Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

  不适用招募中中国NCT05773729

• A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

  II 期招募中中国NCT06302491

• In-utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Bart's Hydrops Fetalis Syndrome

  不适用招募中中国香港NCT05797272

• A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

  III 期招募中美国NCT07517133